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The Nucleoside Hydrolase (NH36) is the main marker of the FML complex of Leishmania donovani, antigen of the licensed 
Leishmune® vaccine for prophylaxis of canine visceral leishmaniasis. As a DNA vaccine in mice, the NH36 induces a TH1 
immune response. Aiming at the identification of the main epitopes of the NH36 recognized by MHC class I and II restricted T 
cells, the sequences of three fragments composed by the aminoacids 1-103 (F1), 104-198 (F2) and 199-314 (F3) were cloned in 
the pET28b plasmid system, expressed them in E. coli Bl21DE3 cells and purified in a Ni-NTA column. Balb/c mice were 
vaccinated with NH36 recombinant protein and Riedel de Haen saponin and challenged with Leishmania chagasi amastigotes. 
The DTH response to leishmanial antigen was significantly increased (70%) in vaccines over controls (p=0.000) remaining 
unchanged after infection and the parasite load in liver suffered a 67.8% significant reduction (p<0.05). Fragments F1 and F3 
were capable of inducing a significantly higher secretion of IFN gamma and TNF alpha by cultured splçeen cells. Both are pro-
inflammatory TH1 cytokines expected in a protective response against visceral leishmaniasis. The IFN gamma/IL-10 ratios 
following stimulation with F1 or with F3 were, repectively, 6.73 (138.57/20.57 pg/ml) and 2.8 (181.42/64.71 pg/ml), indicating 
the induction of a cellular protective immune response, probably related to a TH1 expansion. Taken together, our results of DTH 
response, liver parasitemia and cytokine secretion disclosed that the protective potential of the saponin-NH36 vaccine is probably 
related to the relevant contribution of fragments F1 and F3 stimulating the identification of their major involved epitopes.  
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NH36 is a nucleoside hydrolase of 34.3 kDA and 314 aminoacids which cleaves nucleosides from 
imported DNA to release free purine or pyrimidic bases for Leishmania replication. Accordingly to this very 
relevant function it has been recently recognized as an important and conserved phylogenetic marker of the 
Leishmania genus [1]. It is also the main antigenic marker of the FML complex of Leishmania donovani [2] which, 
together with Quillaja saponaria saponins, constitutes the licensed Leishmune® vaccine for prophylaxis of canine 
visceral leishmaniasis [3]. As a DNA vaccine in mice, the NH36 induces a TH1 immune response [4,5]. Aiming at 
the  identification of  the main epitopes of the NH36 recognized by MHC class I and II restricted T lymphocytes, 
three fragments composed by the aminoacids 1-103 (F1), 104-198 (F2) and 199-314 (F3) were cloned in the pET28b 
plasmid system, expressed in E. coli Bl21DE3 cells and purified in a Ni-NTA column. Balb/c females were 
vaccinated with 3 sc doses of NH36 recombinant protein (100ug/mice) and Riedel de Haen saponin (100ug/mice) 
with a week interval, and challenged with 108 Leishmania chagasi amastigotes obtained from hamster´s spleens.  
Seven days after complete vaccination and 15 days after infection, the antibody response against 2 ug of NH36, F1, 
F2 or F3 fragments was evaluated in sera by an ELISA assay, and the delayed type hypersensitivity (DTH) response 
against  the lysate of 107 stationary phase promastigote of L. donovani was measured in the hind footpads. Fifteen 
days after infection the animals were sacrificed by etherization, 106 splenocytes were cultured for 48h in vitro with 
medium ( negative control) or with L. chagasi stationary phase promastigote lysate (106/well) or NH36, F1, F2 or F3 
recombinant fragments (1 and 5 ug). IFN gamma, TNF alpha and IL-10 cytokines secretions were measured in the 
supernatants of 106 splenocytes obtained as previously described [6] using the Peprotec kit. The parasite load was 
evaluated in Giemsa stained liver smears by microscopical analysis (Leishman Donovan Units (LDU) = number of 
amastigotes/number of cell nuclei x organ weight in mg). For statistical analysis means were compared by ANOVA 
analysis simple factorial test and by one way ANOVA- Tukey´s honestly significant difference method (SPSS for 
windows) or used the 95% confidence interval of the averages. Correlation coefficient analysis was determined on a 
Pearson bivariate, two-tailed test of significance (SPSS).
The results of protection obtained by NH36-saponin mice vaccination are summarized in Figure 1. There 
were not significant differences between vaccinated and control animals regarding their IgG antibody titers before 
(p=0.477) or after infection (p=0.505), but the response to the NH36 protein was significantly higher (p=0.0001) 
than to any of the fragments, after infection (Figure 1A), suggesting that either this approach was not enough 
sensitive to detect the  immunodominant epitopes for antibodies in the recombinant fragments, or that fractionation 
of the NH36 in three fragments disrupted important antibody epitopes present in the whole molecule. The DTH 
response to leishmanial antigen, a very strong protection correlate of visceral leishmaniasis [7], was significantly 
increased (70%) in vaccines over controls (p=0.000) at 24 and 48h after antigen injection, remaining unchanged 
after infection (p=0.916 and p=0.802, respectively), confirming the induction of a strong protective cellular immune 
response (Figure 1B).  
The analysis of cytokine production is resumed in Figure 2 and confirms the presence of cell mediated 
protective immune response. The values obtained in supernatants of splenocytes incubated with no antigen addition 
(negative controls) were discounted from the results obtained with each antigen. Compared to controls, fragments 
F1 and F3 were the only capable of inducing a significant higher secretion of IFN gamma and, among them, F3 was 
more potent (CI95%) (Figure 2A).  Coincidentally, the expression of TNF alpha, the other pro-inflammatory TH1 
cytokine expected in a protective response against visceral leishmaniasis [reviewed in 7,8], was also significantly 
enhanced in vaccines over controls, only in response to the F1 and F3 peptides (Figure 2B). Noteworthy, the IFN 
gamma/IL-10 ratios for stimulation with F1 or F3 were 6.73 (138.57/20.57 pg/ml) and 2.8 (181.42/64.71 pg/ml), 
respectively, indicating the induction of a cellular protective immune response, probably related to a TH1 expansion. 
It is worthy to note that the DTH response of 24 and of 48h were significantly correlated to the increase in IFN 
gamma secretion induced by the F1 (p=0.34 an 0.010, respectively). The characterization of the cells responsible for 
the cytokine secretion is under progress, but our present results already suggest the presence of major MHC epitopes 
involved with the induction of the cellular immune TH1 response, mainly in the F3, followed by F1 fragment of the 
NH36 protein sequence. IL-10 secretion on the other hand, was detected in splenocytes incubated with NH36, F1 
and F3 and was significantly increased after incubation with the total promastigote lysate (Figure 2B) which was 
expected for its Lypophosphoglycan component [9].  
Confirming the results of cellular immune response (Figure 1B, 2A and 2B) generated by NH36-saponin 
vaccination, the parasite load in the liver of vaccinated animals was 67.8% significantly reduced (Figure 1C, 
p<0.05). This efficacy is similar to that achieved against L. donovani infection after vaccination with 100ug of the 
native NH36 glycoprotein isolated by chemical elution (68%) and 100ug of saponin [10]. This result is impressive 
mainly considering that the strain of L. chagasi amastigotes used in this investigation was recently obtained from a 
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dog of endemic area, being therefore strongly virulent for mice. No significant differences were either detected in 
gain of corporal weight or in relative hepato- or splenomegaly despite the detected global increase in weight of 
spleen and liver relative to that of normal uninfected mice (not shown). Taken together our results of DTH response, 
liver parasitemia and IFN gamma and TNF alpha secretion disclosed that the strong protective potential of the 
saponin-NH36 vaccine, against visceral leishmaniasis is probably related to the relevant contribution of fragments 
F1 and F3 and stimulate the identification of their major involved epitopes. 
 Many formulations were developed as first, second or third generation vaccines against leishmaniasis. 
Recently a few of them have been tested as recombinant protein and/or DNA vaccines [reviewed in 7] but 
identification of epitopes recognized by CD8+ and CD4+ cells is less frequent [11]. Our preliminary results of 
identification of the relevant sequences of the NH36 protein are useful in the further development of a potential 
synthetic vaccine against visceral leishmaniasis. 
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Fig.1. Protective response of the NH36-saponin vaccine. (A) IgG serum antibody absorbencies of sera of NH36-
saponin vaccinated or saline treated Balb/c mice before (n=3) and after infection (n=10), against 2ug of the NH36, 
F1, F2 or F3 recombinant fragments by ELISA assay. * indicates significant differences between treatments and # 
indicates significant differences between antigens (ANOVA). 
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Fig.2. Cytokine expression in supernatants of splenocytes of vaccinated and untreated control animals (n=7/group). 
Fifteen days after infection, splenocytes were obtained and incubated in the presence of RPMI medium, L. chagasi
promastigote lysate (106) and the NH36, F1, F2 and F3 recombinant antigens for 48h at 37oC under 5% of CO2. 
Cytokine expression was measured by an ELISA assay. (A) For IFN gamma assay splenocytes were incubated with 
1ug of NH36, F1, F2 and F3 recombinant antigens. (B) For TNF alpha and IL-10 assays splenocytes were incubated 
with 5 and 1ug of NH36, F1, F2 and F3 recombinant antigens, respectively. (*) indicates significant differences 
between treatments and # indicates significant differences between antigens (ANOVA and CI95%). 
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